Top Markets
Coin of the day
Medigen Biotechnology Corp. Medigen Biotechnology Corp.

Medigen Biotechnology Corp.

3176
Classement en actions #19061
Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated... Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated to inventing therapies for liver diseases and various forms of cancer. Its product portfolio includes advanced cell therapies like MAGICELL-NK, which leverages natural killer cells, and MAGICELL-GDT, a T-cell-based treatment. A significant pipeline asset for Medigen is OBP-301. This therapeutic has completed Phase I clinical trials for combination therapy in esophageal cancer in Japan. It is currently being evaluated in ongoing Phase I trials in Japan, combining it with immune checkpoint inhibitors (ICIs) for esophageal cancer, and has advanced to Phase II studies in the United States, investigating its use with ICIs for both esophageal and gastric cancer. Established in 1999, Medigen Biotechnology Corp. maintains its corporate headquarters in Taipei, Taiwan.
Prix de l'action
$1.27
Capitalisation boursière
$176.31M
Changement (1 jour)
5.57%
Changement (1 an)
29.36%
Pays
TW
Échange Medigen Biotechnology Corp. (3176)

Catégorie

Ratio P/B pour Medigen Biotechnology Corp. (3176)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Medigen Biotechnology Corp., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Medigen Biotechnology Corp. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH